Lettland - Lettisch - Zāļu valsts aģentūra

sandoz d.d., slovenia - budesonidum, formoteroli fumaras dihydricus - inhalācijas pulveris, dozēts - 160 μg/4,5 μg/inhalācijā

Lettland - Lettisch - Zāļu valsts aģentūra

lfb biomedicaments, france - cilvēka villebranda faktors - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 500 sv

Lettland - Lettisch - Zāļu valsts aģentūra

lfb biomedicaments, france - cilvēka villebranda faktors - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 2000 sv

Lettland - Lettisch - Pārtikas un veterinārais dienests, Zemkopības ministrija

sia ''medisana'' 40003568616 o. vācieša iela 13, rīga, lv-1004 - cits, tējas paciņa - cits - paredzēts lietošanai cilvēkiem ar veselības traucējumiem – fenilketonūriju un glutēna nepanesību

Lettland - Lettisch - Pārtikas un veterinārais dienests, Zemkopības ministrija

sia "medisana" - makaronu iztrādājums

Lettland - Lettisch - Pārtikas un veterinārais dienests, Zemkopības ministrija

sia "medisana" - pulveris

Lettland - Lettisch - Zāļu valsts aģentūra

reckitt benckiser (poland) s.a., poland - ibuprofēns - Ārstnieciskais plāksteris - 200 mg

Europäische Union - Lettisch - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - rekombinanto vezikulārā stomatīta vīruss (celms, indiana), ar dzēšanas aploksnes glikoproteīnu, aizstāj ar zaira ebolavirus (celms kikwit 1995) virsmas glikoproteīnu - hemorāģisko drudzi, ebola - vakcīnas - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. izmantot ervebo būtu saskaņā ar oficiālās rekomendācijas.

Europäische Union - Lettisch - EMA (European Medicines Agency)

santen oy - netarsudil - glaucoma, open-angle; ocular hypertension - oftalmoloģiskie līdzekļi - samazināt paaugstinātu intraokulāro spiedienu (ias) pieaugušiem pacientiem ar primāra atvērta kakta glaukoma vai acs hipertensijas.

Europäische Union - Lettisch - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcīnas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.